Vir Biotechnology Reports Strong Q2 2026 on Astellas Deal and CHD Pipeline Progress
Event summary
- Vir Biotechnology reported $80.1M net income for Q2 2026, driven by a $240M upfront payment from Astellas.
- Completed enrollment in Phase 3 ECLIPSE registrational program for chronic hepatitis delta (CHD).
- Week 96 SOLSTICE data showed 88% of patients achieved undetectable HDV RNA with elebsiran and tobevibart combination therapy.
- Initiated additional Phase 1 dose-expansion cohorts for VIR-5500 in prostate cancer collaboration with Astellas.
The big picture
Vir Biotechnology's Q2 2026 results highlight its strategic shift toward oncology with the Astellas collaboration, complementing its infectious disease focus. The CHD pipeline progress positions Vir as a key player in addressing this severe liver condition, while the prostate cancer program expands its footprint in high-unmet-need solid tumors.
What we're watching
- Regulatory Milestones
- Whether the ECLIPSE program data will support global regulatory filings for CHD treatment.
- Pipeline Execution
- The pace at which Vir advances VIR-5500 into pivotal Phase 3 trials in prostate cancer.
- Financial Runway
- How the $1.01B cash position will support operations through mid-2028.
Related topics